Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma

Yves-Paul Vandewynckel; Anja Geerts; Xavier Verhelst; Hans Van Vlierberghe

doi:10.1002/ccr3.34

Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma

Clin Case Rep. 2014 Feb;2(1):4-6. doi: 10.1002/ccr3.34. Epub 2013 Dec 31.

Authors

Yves-Paul Vandewynckel¹, Anja Geerts¹, Xavier Verhelst¹, Hans Van Vlierberghe¹

Affiliation

¹ Department of Hepatology and Gastroenterology, Ghent University B-9000, Ghent, Belgium.

PMID: 25356226
PMCID: PMC4184762
DOI: 10.1002/ccr3.34

Abstract

Sorafenib is the standard treatment of hepatocellular carcinoma (HCC). However, fibrolamellar HCC was not included in sorafenib trials. The case is a 26-year-old man with fibrolamellar HCC, who had a cerebrovascular accident (CVA) while being treated with sorafenib. This illustrates a probable relationship between use of sorafenib and CVA in low cardiovascular risk patients.

Keywords: Carcinoma; drug toxicity; fibrolamellar hepatocellular carcinoma; hepatocellular; sorafenib; stroke.